Bone-targeted celastrol nanocarrier suppresses osteoclastogenesis in postmenopausal osteoporosis.

ABSTRACT: Osteoporosis is a metabolic disorder characterized by progressive bone loss, particularly affecting postmenopausal women. Excessive osteoclast activity contributes to bone resorption and skeletal fragility. Celastrol, a natural triterpene, has demonstrated anti-inflammatory and anti-resorptive effects, but its clinical application is limited by poor solubility and systemic toxicity. In this study, we engineered a bone-targeted nano-sustained-release system using mesoporous silica nanoparticles loaded with celastrol. The nanocarrier displayed high bone affinity, sustained drug release, and favorable biocompatibility. In vitro, it suppressed RANKL-induced osteoclast formation and function by downregulating NF-κB and MAPK signaling. In vivo, treatment of ovariectomized rats improved bone mine

SUBMITTER: Yu X 

PROVIDER: S-EPMC12578893 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature